[Based on Japanese GAAP]
Operating Results
Overview of Operating Results
-
Net sales
35,253 million yen
YOY 8.9%
-
Operating profit
2,649 million yen
YOY (20.8)%
-
Ordinary profit
2,660 million yen
YOY (19.7)%
-
Profit attributable to owners of parent
2,226 million yen
YOY (13.0)%
-
Earnings per share
78.49 yen
YOY (13.1)%
During the current interim consolidated accounting period, while the domestic economy continued to recover gradually due to improvements in employment and income environments, the outlook remained uncertain due to factors such as continued price increases, developments in U.S. trade policies, and the prolonged situations in Ukraine and the Middle East. In addition, the pharmaceuticals business, which is the core of our Group, continued to face a difficult operating environment due to the impact of ongoing policies to control medical expenses, such as annual NHI drug price revisions. In the Group’s business, however, net sales increased by 2,881 million yen year on year (YoY) to 35,253 million yen (up 8.9% YoY) due to growth in the pharmaceutical and veterinary pharmaceutical businesses. On the other hand, due in part to the increase in R&D costs etc., operating profit decreased to 2,649 million yen (down 20.8% YoY) and ordinary profit decreased to 2,660 million yen (down 19.7% YoY), and profit attributable to owners of parent decreased to 2,226 million yen (down 13.0% YoY), all showing a decline in profits.
Segment
Net sales
(Millions of yen)
| Segment name | 1Q | 2Q | 3Q | Full year |
|---|---|---|---|---|
| Pharmaceutical business | 14,515 | 29,255 | ||
| Animal health business | 1,841 | 3,765 | ||
| Overseas businesses | 1,226 | 2,133 | ||
| Other businesses | 58 | 99 |
(i) Pharmaceutical business
The pharmaceutical business, which focuses on the three fields: internal medicine, obstetrics and gynecology, and urology, showed favorable trends overall, despite the impact of annual NHI drug price revisions. A look at results by product demonstrates that the outcomes within the field of obstetrics and gynecology have been primarily driven by the consistent growth of the uterine fibroid and endometriosis agent RELUMINA (relugolix), which reached 5,692 million yen (up 5.2% YoY), and the dysmenorrhea agent DroEthi (drospirenone/ethinylestradiol) continued to significantly contribute to performance following the previous year, with sales of 4,109 million yen (up 14.5% YoY). Sales also grew steadily in the internal medicine area, as sales of the thyroid hormone agent THYRADIN (levothyroxine), our main product in this field, grew to 4,306 million yen (up 6.3% YoY) and those of the poorly absorbable rifamycin antimicrobial agent RIFXIMA (rifaximin) to 3,880 million yen (up 20.2% YoY), reflecting the positive impact of the NHI drug price revision. In the urology field, sales of the LH-RH derivative microcapsule sustained-release agent LEUPRORELIN were 1,908 million yen (down 6.3% YoY).
As a result of the above factors, the segment sales were 29,255 million yen (up 2.2% YoY), and the segment profit was 3,119 million yen (down 18.4% YoY), mainly due to an increase in R&D expenses and other costs.
(ii) Animal health business
Sales of the animal health business, which sells products such as veterinary pharmaceuticals and feed additives, were 3,765 million yen (up 3.4% YoY), mainly due to increased sales in veterinary pharmaceuticals. Segment profit also increased to 282 million yen (up 59.7% YoY).
(iii) Overseas businesses
"Overseas business", a new reportable segment, was added following the consolidation of Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical company, as a consolidated subsidiary in the previous consolidated fiscal year. For the overseas business, segment sales were 2,133 million yen and segment profit was 132 million yen.
(iv) Other businesses
Sales results for other businesses, which include clinical testing and medical devices, grew to 99 million yen (down 11.8% YoY). Segment loss was 15 million yen (vs. a loss of 4 million yen in the same period of the previous year).
Financial Position
Overview of Financial Position Summary
-
Total assets
108,773 million yen
Change from end of previous fiscal year 4.7%
-
Net assets
72,594 million yen
Change from end of previous fiscal year 1.5%
-
Equity ratio
61.5 %
Change from end of previous fiscal year (1.4)point
Overview of Financial Position
(Assets)
Total assets at the end of the current interim consolidated accounting period stood at 108,773 million yen, up 4,884 million yen from the end of the previous consolidated fiscal year. This figure was due mainly to increases in securities, and accounts receivable-trade.
(Liabilities)
Total liabilities at the end of the current interim consolidated accounting period stood at 36,178 million yen, up 3,845 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to increases in long-term borrowings, and accounts payable-trade.
(Net assets)
Total assets at the end of the current interim consolidated accounting period stood at 72,594 million yen, up 1,038 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to retained earnings resulting from the recording of profit attributable to owners of parent and an increase in valuation difference on available-for-sale securities.
The resulting equity ratio was 61.5%, down 1.4 percentage points from the end of the previous consolidated fiscal year.
Cash Flow Summary
-
Cash flows from operating activities
1,105 million yen
-
Cash flows from investing activities
(5,959) million yen
-
Cash flows from financing activities
(1,382) million yen
-
Cash and cash equivalents at end of period
7,062 million yen
Overview of Cash Flow Position
The balance of cash and cash equivalents (hereinafter referred to as “Net cash”) at the end of the current interim consolidated accounting period stood at 7,062 million yen, a decrease of 3,540 million yen from the end of the previous consolidated fiscal year.
The standing of each type of cash flow for the current interim consolidated accounting period, and major contributing factors of each, are summarized below.
(Cash flows from operating activities)
Net cash provided by operating activities was 1,105 million yen (vs. a gain of 1,159 million yen in the same period of the previous fiscal year). This was due mainly to the recording of interim net income before income taxes and depreciation, despite decreases in trade payables and increases in trade receivables.
(Cash flows from investing activities)
Net cash used in investing activities was 5,959 million yen (vs. a loss of 1,783 million yen in the same period of the previous fiscal year). This was due mainly to the acquisition of shares of subsidiaries and associates, and of property, plant and equipment.
(Cash flows from financing activities)
Net cash provided by financing activities was 1,382 million yen (vs. a loss of 2,406 million yen in the same period of the previous year). This was due mainly to proceeds from long-term borrowings.